Page 1

SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 Form 20 - F □ REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 Or □ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 Or □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Or □ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-36203 Can - Fite BioPharma Ltd. ( Exact name of Registrant as specified in its charter ) Can - Fite BioPharma Ltd. , an Israeli Limited Company ( Translation of the Registrant's name into English ) Israel ( Jurisdiction of incorporation ) 10 Bareket Street , Kiryat Matalon , P.O. Box 7537 , Petah - Tikva 4951778 , Israel ( Address of principal executive offices ) Motti Farbstein Chief Operating and Financial Officer Tel : +972 ( 3 ) 924-1114 Fax : +972 ( 3 ) 924-9378 motti@canfite.co.il 10 Bareket Street , Kiryat Matalon , P.O. Box 7537 , Petah - Tikva 4951778 , Israel ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act : Title of each class American Depositary Shares , each representing 30 Ordinary Shares , par value NIS 0.25 per share * Trading Symbol ( s ) CANF Name of each exchange on which registered NYSE American Securities registered or to be registered pursuant to Section 12 ( g ) of the Act : None Securities for which there is a reporting obligation pursuant to Section 15 ( d ) of the Act : None